Table 1.
Clinicopathological characteristics of NMIBC patients who underwent initial intravesical BCG treatment after TURB.
| Variables | Total (N = 385) |
|---|---|
| Age | 72.6 ± 10.6 |
| SEX | |
| Man | 327 (84.9%) |
| Woman | 58 (15.1%) |
| BMI | 24.2 ± 3.1 |
| Hypertension | 150 (39.0%) |
| Diabetes | 70 (18.2%) |
| Lung disease | 30 (7.8%) |
| White blood cell | 6.5 ± 1.7 |
| Platelet | 218.9 ± 56.7 |
| NLR | 2.2 ± 1.2 |
| dNLR | 1.5 ± 0.7 |
| PLR | 122.6 ± 50.6 |
| Hemoglobin | 14.1 ± 2.2 |
| Serum creatinine | 1.1 ± 0.4 |
| eGFR | 73.0 ± 17.5 |
| pT STAGE | |
| Tis | 47 (12.2%) |
| Ta | 86 (22.3%) |
| T1 | 252 (65.5%) |
| TUMOR GRADE | |
| None | 9 (2.3%) |
| Low grade | 50 (13.0%) |
| High grade | 326 (84.7%) |
| Concurrent CIS | 105 (27.3%) |
| LVI | 8 (2.1%) |
| TUMOR NUMBER | |
| 1 | 148 (38.4%) |
| 2–7 | 186 (48.3%) |
| ≧3 | 51 (13.2%) |
| TUMOR SIZE | |
| <3 cm | 290 (75.3%) |
| ≧3 cm | 95 (24.7%) |
| Radical cystectomy (N/Person-Years) | 51 (13.2%)/84.8 |
| Upper urinary tract recurrence (N/Person-Years) | 16 (4.2%)/72.1 |
| Recurrence (N/Person-Years) | 186 (48.3%)/669.3 |
| Progression (N/Person-Years) | 44 (11.4%)/116.1 |
| Cancer specific mortality (N/Person-Years) | 18 (4.7%)/103.6 |
| Total mortality (N/Person-Years) | 70 (18.2%)/300.6 |
NMIBC, non-muscle invasive bladder cancer; BMI, body mass index; SIR, systemic inflammatory response; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived NLR; PLR, platelet-lymphocyte ratio; CIS, carcinoma in situ.